Stockreport
NovoCure GAAP EPS of -$0.22 beats by $0.19, revenue of $174.35M beats by $0.99M [Seeking Alpha]
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
Novocure's guidance for the full year 2026 is summarized below. Total net revenues $675 million–$705 million Adjusted EBITDA* $(20) million - $0 million Click to enlarge Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up More on NovoCure NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching Why NovoCure Is No Longer A Clear Sell At These Lows NovoCure Limited (NVCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript NovoCure Q4 2025 Earnings Preview Novocure shares surge after FDA approves Optune Pax for pancreatic cancer Recommended For You More Trending News
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | NVCR | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
NVCR alerts
NVCR alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
NEWS
NEWS
- Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer[Business Wire]
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer[Business Wire]
- NovoCure Limited Q4 2025 Earnings Call Summary [Yahoo! Finance][Yahoo! Finance]
- Novocure to Participate in 2026 Leerink Global Healthcare Conference[Business Wire]
- NovoCure (NVCR) had its price target raised by HC Wainwright from $47.00 to $49.00. They now have a "buy" rating on the stock.[MarketBeat]
- More
NVCR
SEC Filings
SEC Filings
- 3/26/26 - Form SCHEDULE
- 3/26/26 - Form 8-K
- 3/5/26 - Form 4
- NVCR's page on the SEC website
- More